SAN DIEGO, Oct. 3, 2024–(BUSINESS WIRE)–CureMetrix® demonstrates the use of its investigational AI-enabled automated breast artery calcification (BAC) detection software in mammograms in a new peer-reviewed research study announced that the feasibility of this has been demonstrated. Provides personalized risk predictions for mortality and cardiovascular disease in women. BAC reporting was possible and reliable using AI algorithms within a proprietary, validated clinical trial software called cmAngio®*.
The study, “Automated thoracic artery calcification score is associated with cardiovascular outcomes and mortality,” published online in the Journal of the American College of Cardiology (JACC) Advances on September 26, 2024, We verified the utility of a new AI algorithm for BAC detection and segmentation.
In this paper, we evaluated the association between BAC (both presence and extent) and cardiovascular disease (CVD) outcomes. This retrospective study followed over 18,000 women for up to 11 years and used AI-generated BAC scores evaluated as both a dichotomous and continuous variable.
Regression analyzes assessed the association between BAC and adverse prevalent and incidental outcomes such as acute myocardial infarction, heart failure, stroke, and mortality. Analyzes were adjusted for age, race, diabetes, smoking, blood pressure, cholesterol, and history of CVD and chronic kidney disease.
Kevin Harris, President of CureMetrix, said, “The potential to use AI to accurately detect and score breast artery calcification in mammography and improve personalized CVD risk stratification is proving both viable and clinically viable. “It’s very exciting that the link has been scientifically verified.” “We fully support collaboration between cardiology, radiology, and primary care teams to accelerate the use of technology to improve preventive care for women.”
The study found that for every 10-point increase in an individual’s BAC score (Bradley Score™: 0-100), the risk of death was 8% higher (HR 1.08 (95% CI 1.06-1.11)) and the composite mortality rate was 8% It was shown that high Outcome risk (HR 1.08 (95% CI 1.06-1.10)). Notably, BAC was particularly predictive among young women aged 40 to 59 years. Patients with BAC were three times more likely to develop adverse outcomes including myocardial infarction, stroke, heart failure, and death (composite outcome OR = 3.18, 95% CI: 2.81 – 3.61), highlighting the potential benefits of early intervention. I am.
The study was conducted using de-identified patient records from the University of California, San Diego.
the story continues
“We hope that these study results will increase awareness of the utility of thoracic artery calcification as a cardiac risk factor. Our goal is to ultimately extend established routine screening to cardiovascular in preventive care,” said FACC senior author Lori B. Daniels, MD. The study director is a professor of cardiology at the University of California, San Diego School of Medicine and a board-certified cardiologist at UC San Diego Health.
Disclosure: For more information, please see the full paper at https://www.jacc.org/doi/10.1016/j.jacadv.2024.101283. Authors QMB, NN, ME, and LBD serve as consultants for CureMetrix. Authors RM and JW are employees of CureMetrix. The remaining authors have nothing to disclose. The first and senior authors had access to all data and independently prepared the manuscript.
*cmAngio® is FDA cleared for BAC detection and localization. This device is not a diagnostic tool for heart or other specific diseases, nor is it intended to predict the onset of any disease. The version that outputs the Bradley score is for research use only and is not currently intended for commercial distribution.
About Curemetrics
CureMetrix is committed to advancing technology that improves disease detection and survival rates around the world. CureMetrix has partnered with practicing radiologists, cardiologists, and reputable institutions around the world to develop algorithms that impact women’s healthcare. From breast cancer to heart disease to kidney disease, we believe AI can be used to improve patient outcomes and expand the impact and value of screening programs around the world. Our mission is to save lives with earlier and more accurate detection, help improve clinical and financial outcomes, and provide technology that physicians, health systems, and patients can trust with confidence. Visit www.CureMetrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003639715/en/
contact address
jenny bowling
jenni.bowring@padillaco.com
651.226.3858
